Guided Therapeutics (GTHP) Amortization of Deferred Charges (2018 - 2025)
Guided Therapeutics (GTHP) reported Amortization of Deferred Charges of $172000.0 for Q4 2025, up 352.63% on a YoY basis from $38000.0 in Q4 2024, and up 373.02% sequentially from -$63000.0 in Q3 2025.
Guided Therapeutics (GTHP) Amortization of Deferred Charges (2018 - 2025) Analysis & Trends
Guided Therapeutics (GTHP) has 8 years of Amortization of Deferred Charges data on file, last reported at $172000.0 in Q4 2025.
- For the quarter ending Q4 2025, Amortization of Deferred Charges rose 352.63% year-over-year to $172000.0; the trailing twelve-month figure through Dec 2025 stood at $244000.0 (up 121.82% YoY), and the FY2025 full-year result was $244000.0, up 121.82% from the prior year.
- Amortization of Deferred Charges improved to $172000.0 in Q4 2025, from -$63000.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $172000.0 in Q2 2021 to a low of -$168000.0 in Q4 2021.
- A 5-year average of $32750.0 and a median of $32000.0 in 2022 frame the typical range for Amortization of Deferred Charges.
- Peak annual rise in Amortization of Deferred Charges reached 352.63% in 2025, while the deepest fall reached 386.36% in 2025.
- Tracing GTHP's Amortization of Deferred Charges over 5 years: stood at -$168000.0 in 2021, then jumped by 119.05% to $32000.0 in 2022, then sank by 37.5% to $20000.0 in 2023, then jumped by 90.0% to $38000.0 in 2024, then soared by 352.63% to $172000.0 in 2025.
- Business Quant data shows GTHP's Amortization of Deferred Charges at $172000.0 in Q4 2025, -$63000.0 in Q3 2025, and $68000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | Guided Therapeutics | 21.96 Mn | 21.89 Mn | 458,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 172,000.00 |
| Dec 31, 2025 | 172,000.00 |
| Sep 30, 2025 | -63,000.00 |
| Sep 30, 2025 | -63,000.00 |
| Jun 30, 2025 | 68,000.00 |
| Jun 30, 2025 | 68,000.00 |
| Mar 31, 2025 | 67,000.00 |
| Mar 31, 2025 | 67,000.00 |
| Dec 31, 2024 | 38,000.00 |
| Dec 31, 2024 | 38,000.00 |
| Sep 30, 2024 | 22,000.00 |
| Sep 30, 2024 | 22,000.00 |
| Jun 30, 2024 | 29,000.00 |
| Jun 30, 2024 | 29,000.00 |
| Mar 31, 2024 | 21,000.00 |
| Mar 31, 2024 | 21,000.00 |
| Dec 31, 2023 | 20,000.00 |
| Dec 31, 2023 | 20,000.00 |
| Sep 30, 2023 | -9,000.00 |
| Sep 30, 2023 | -9,000.00 |